Winter is former deputy director of the Laboratory of Molecular Biology at the Medical Research Council in Cambridge, U.K., and founder
of several biotechnology companies; he was appointed Master of Trinity College at the University of Cambridge in December 2011.
Syngenta arranged royalty - free access to the patents and intellectual property, held
by several biotechnology companies, for a number of key technologies used in Golden Rice.
He has served as a business advisor to Oisin since its inception and has served
on several biotechnology company advisory boards, specializing in business strategy and capital formation.
Pestell has published more than 600 works and is the most frequently cited scientist in his fields of cell - cycle and prostate cancer.He has been the reviewer of 18 scientific journals, has served on editorial boards of six journals and has
founded several biotechnology companies.
He has been a founder or co-founder
of several biotechnology companies and his work has included protein therapeutics (Receptor BioLogix, Inc., 2003 - 2008), small molecules (NewBiotics, Inc., 1997 - 2002), gene therapy (Canji, Inc. / Schering - Plough Corporation, 1992 - 1997), and monoclonal antibody therapeutics (Genentech, Inc. 1980 - 1992).
We are quite aware that there are
several biotechnology companies both large and small in the United States of America and Canada which is why we are following the due process of establishing a business so as to compete favorable with them.
Several biotechnology companies are using the gene editing technique in an effort to develop therapies for treating genetic diseases, including CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine.
Dr. Kinet has conducted extensive research and development of new therapies, and he is a Board member of
several biotechnology companies, and a Director at UCB Pharma.